Attorney Docket No.: PU4804USw

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shewchuk et al.			of: Shewchuk et al.	Confirmation No.: 7149
Serial No.: 10/543,046			3,046	Group Art Unit: 1656
Filing C	ate	: July :	21, 2005	Examiner: David J. Steadman
For:	ER	BB4 CO	D-CRYSTAL	·
Commi P.O. B	ssic ox 1	ner for 450	NDMENT Patents 2313-1450	
		SI	UPPLEMENTAL INFORMATION	I DISCLOSURE STATEMENT
be consof 37 C	side	red by	the Examiner and officially made	ntified on Form PTO-1449 appended hereto e of record in accordance with the provisions
·	[ ]	Copies (37 CF A copy No Search unders	is submitted herewith. An Report are listed on the attached	ed in parent application  Fort which issued on International Application all of the publications cited in the International ed form PTO-1449, and Applicants plied to the U.S. Patent Office by the
Α.	[]	month:	s of the filing date of the above a	submitted herewith is being filed within three application or date of entry into the national before the mailing date of a first Office Action last. 37 CFR §1.97(b).
	OR			
	[]	the ma		nt submitted herewith is being filed before rafter the filing of a Request for Continued 7 CFR §1.97(b)(4)).
В.	[X]	months nationa mailing	s of the filing date of the above a al stage as set forth in §1.491 of	

Attorney Docket No.: PU4804USw [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [X] Applicant elects the option to pay the fee set forth in 37 CFR §1.17(p) for submission of an Information Disclosure Statement under §1.97(c) (\$180.00). [ ] The Information Disclosure Statement transmitted herewith is being filed after a final C. Office Action under §1.113, or a Notice of Allowance under §1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. In accordance with the requirements of 37 CFR §1.97(d): Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. OR Applicant hereby petitions for the consideration of the accompanying Information [] Disclosure Statement. 37 CFR §1.97(d)(ii). The petition fee set forth in §1.17(i)(1) (\$130.00) is submitted herewith. [X] Please charge any required fees to Deposit Account No. 07-1392. [ ] A duplicate copy of this paper is attached. Respectfully submitted, athy L. Coulter

Kathryn L. Coulter Attorney of Record

Registration No. 45,889

Date: 9/29/2008

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1467 Facsimile: (919) 483-7988